Cargando…

CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer

It is desirable to have a biomarker which can facilitate low‐dose CT in diagnosis of early stage lung cancer. CTAPIII/CXCL7 is reported to be a potential biomarker for diagnosis of early lung cancer. In this study, we investigated the serum level of CTAPIII/CXCL7 in patients at different stage of lu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Qiang, Li, Encheng, Liu, Yonge, Xie, Wenli, Huang, Chun, Song, Jiaqi, Zhang, Wei, Zheng, Yijie, Wang, Huiling, Wang, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806116/ https://www.ncbi.nlm.nih.gov/pubmed/29356357 http://dx.doi.org/10.1002/cam4.1292

Ejemplares similares

Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non‐small cell lung cancer
por: Deng, Jie, et al.
Publicado: (2022)

CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients
por: Wang, Cuini, et al.
Publicado: (2016)

Serum CXCL5 level is associated with tumor progression in penile cancer
por: Mo, Miao, et al.
Publicado: (2021)

Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
por: Chu, Ling-Yu, et al.
Publicado: (2021)

CXCL9: evidence and contradictions for its role in tumor progression
por: Ding, Qiang, et al.
Publicado: (2016)

Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
por: Moledina, Dennis G., et al.
Publicado: (2023)

Up-regulation of CXCL8 expression is associated with a poor prognosis and enhances tumor cell malignant behaviors in liver cancer
por: Yang, Song, et al.
Publicado: (2020)

Serum biomarker panels for the diagnosis of gastric cancer
por: Wu, Dan, et al.
Publicado: (2019)

Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma
por: Liu, Yin-Qiao, et al.
Publicado: (2022)

Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma
por: Han, Ke‐qi, et al.
Publicado: (2016)

The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution
por: Wang, Gui-Zhen, et al.
Publicado: (2015)

Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer
por: Zang, Yuan‐sheng, et al.
Publicado: (2019)

Circulating lncRNA DANCR as a potential auxillary biomarker for the diagnosis and prognostic prediction of colorectal cancer
por: Shen, Xianjuan, et al.
Publicado: (2020)

ARG1 and CXCL2 are potential biomarkers target for psoriasis patients
por: Wang, Huilin, et al.
Publicado: (2022)

Long non-coding RNA DSCAM-AS1 contributes to the tumorigenesis of cervical cancer by targeting miR-877-5p/ATXN7L3 axis
por: Liang, Jie, et al.
Publicado: (2020)

Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China
por: Shan, Xia, et al.
Publicado: (2018)

Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
por: Zhang, Mingjie, et al.
Publicado: (2020)

Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer
por: Li, Longhai, et al.
Publicado: (2019)

Multi‐marker algorithms based on CXCL13, IL‐10, sIL‐2 receptor, and β2‐microglobulin in cerebrospinal fluid to diagnose CNS lymphoma
por: Maeyama, Masahiro, et al.
Publicado: (2020)

Urinary exosomal long noncoding RNAs serve as biomarkers for early detection of non-small cell lung cancer
por: Lin, Quan, et al.
Publicado: (2021)

WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma
por: Yuan, Qihang, et al.
Publicado: (2021)

Fingolimod inhibits proliferation and epithelial–mesenchymal transition in sacral chordoma by inactivating IL-6/STAT3 signalling
por: Wang, Jiaqi, et al.
Publicado: (2020)

Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection
por: Gutteridge, Alice, et al.
Publicado: (2017)

METTL7B (methyltransferase-like 7B) identification as a novel biomarker for lung adenocarcinoma
por: Ali, Jawad, et al.
Publicado: (2020)

Expression level of CXCL7 in peripheral blood cells is a potential biomarker for the diagnosis of renal cell carcinoma
por: Kinouchi, Toshiro, et al.
Publicado: (2017)

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects
por: Suarez-Carmona, Meggy, et al.
Publicado: (2021)

Plasma CXCL14 as a Candidate Biomarker for the Diagnosis of Lung Cancer
por: Tian, Peng-Fei, et al.
Publicado: (2022)

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition
por: Crist, McKenzie, et al.
Publicado: (2022)

A qualitative signature for early diagnosis of hepatocellular carcinoma based on relative expression orderings
por: Ao, Lu, et al.
Publicado: (2018)

Sulfiredoxin‐1 is a promising novel prognostic biomarker for hepatocellular carcinoma
por: Rao, Qian‐Wen, et al.
Publicado: (2020)

CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B
por: Yu, Xin, et al.
Publicado: (2022)

CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer
por: Zajkowska, Monika, et al.
Publicado: (2023)

Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis
por: Wu, Sheng, et al.
Publicado: (2012)

Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma
por: Xue, Li‐Jun, et al.
Publicado: (2017)

Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression
por: Wang, Ying‐Yi, et al.
Publicado: (2020)

Serum Chemokine CXCL7 as a Potential Novel Biomarker for Obstructive Colorectal Cancer
por: Li, Longhai, et al.
Publicado: (2021)

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
por: Shigeta, Kohei, et al.
Publicado: (2020)

Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma
por: Li, Junfeng, et al.
Publicado: (2023)

Identification of a 7‐microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection
por: Zhang, Huo, et al.
Publicado: (2019)

ITGB4 as a novel serum diagnosis biomarker and potential therapeutic target for colorectal cancer
por: Jiang, Xia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hlaglj7ojsafv3tquss2j4eui8